Podcasts about professor murray

John Murray was one of the outstanding Reformed theologians of the 1900s. Earnest and serious, he was also deeply affectionate and much beloved of his students and colleagues. On the 50th anniversary of his death in 1975 we take time to consider his life, theology, and legacy to us today.   Featured Resources: – Excerpt from Iain Murray, 'John Murray: A Memorial with Tributes' in Banner of Truth Magazine, Issue 143–4 (August/September 1975), Chapter 4, 'Glimpses of Work in the War Years', p. 45–49. N.B. Iain Murray's Life of John Murray (v. i.) represents an enlargement of this memorial with additional information.  – Tribute to Professor Murray by Geoffrey Thomas, Banner of Truth Magazine, Issue 143–4 (August/September 1975), p. 75–80. – Murray, John, 'The Death of Christ' in The Collected Writings of John Murray: Volume 1, The Claims of Truth (Edinburgh: Banner of Truth Trust, 1976, 2024), p. 36–40.   Note: Professor Murray's response to Geoff Thomas' question about whether the New Testament teaches that every Christian should witness for his Saviour: 'Later in the week he came to me after a lecture and gave me a piece of paper with these textual references written upon it: Acts 8:4; 18:26; 1 Cor. 1:5, 17; 1 Cor. 2:1–5; 1 Cor. 4:15; 1 Cor. 11:4, 5; 2 Cor. 3:8–12; compared with 1 Cor. 4:13; 2 Cor. 5:12, 18, 19; 2 Cor. 8:7; Eph. 4:15, 29; Eph. 5:11; Eph. 6:17; Phil. 1:14–18; 1 Thess. 1:8; Titus 2:3, 4; 1 Peter 3:15.'     Cover art: juxtaposition of a view of Loch Migdale, looking east towards Badbea (pron. 'Bad-bay'), and a picture of Professor Murray taken at a Banner of Truth ministers' conference in Leicester, c. 1965.   Further Reading: Murray, Iain H., The Life of John Murray (Paperback, 240 pages) Murray, John, Collected Writings of John Murray (4-volume clothbound set, 1224 pages) — Volume 1: The Claims of Truth (Clothbound, 388 pages) — Volume 2: Systematic Theology (Clothbound, 428 pages) — Volume 3: Life, Sermons, Reviews (Clothbound, 404 pages) — Volume 4: Studies in Theology (Clothbound, 400 pages) Murray, John, The Free Offer of the Gospel (Booklet, 32 pages) Murray, John, Redemption Accomplished and Applied (Paperback, 200 pages)   Digging Deeper: Listen to Dr. Donald John Maclean's lecture on The Theological Method of John Murray (at Puritan Reformed Theological Seminary).   Explore the work of the Banner of Truth: www.banneroftruth.org Subscribe to the Magazine (print/digital/both): www.banneroftruth.org/magazine Leave us your feedback or a testimony: www.speakpipe.com/magazinepodcast

WATCH ON YOUTUBE: https://youtu.be/8Ssqnccv2_INEW SERIES WHERE I ASK FASCINATING PEOPLE 10 QUESTIONS in 10 MINUTES!Ep #3 is with the scientific advisor of the film 'Ex Machina', Professor Murray Shanahan. Murray works at Google DeepMind as a Principal Research Scientist, and is a Professor of Cognitive Robotics at Imperial College London. He is an expert in Artificial Intelligence (AI).Subscribe for new episodes every week!

Between Metropolis and Star Wars lies a 50 year wasteland of terrible movie robots. Today, we have a cheeky bonus episode. In our last episode, Professor Murray made the outrageous claim that Tetsujin 28 GO started a billion dollar, massive robot industry. So, we thought we'd look at the great grandchild of Tetsujin, the first TRANSFORMERS film. Will there be more than meets the eye? Let's hope so.WARNING! The S**t-bomb is sometimes uttered but nothing more. Twitter: @FiftyYOSRInsta: @FiftyYOSRTikTok: @FiftyYOSRNOTESHISTORY OF TRANSFORMERS TOYS 1984https://www.youtube.com/watch?v=1RZrp1QPX5w TRANSFORMERS CARTOON EPISODE 1https://www.youtube.com/watch?v=Y1ujpoDlgRU&list=PLD3dCMp2WHiwrVPo2XaZpkWp3K3xpx3h8 HOW HOLLYWOOD GETS THE MILITARY AS A CO-STARhttps://www.military.com/off-duty/how-hollywood-films-get-us-military-co-star.html THE HISTORY OF NOKIA PHONES IN MOVIEShttps://community.phones.nokia.com/discussion/41180/the-history-of-nokia-phones-movie-editionTIFFANY EXPLAINS IT ALL: THE EPISODE ABOUT TRANSFORMERShttps://www.youtube.com/watch?v=SVV7rTB-RzA QUEER ELEMENTS OF BEAST WARS & BEAST MACHINEShttps://safeschoolssouthflorida.org/transformers-impact-on-queer-culture-beast-wars-beast-machines-and-beyond/#:~:text=The%20Transformers%20franchise%20has%20long,fearless%20as%20their%20masc%20counterparts Get bonus content on Patreon Hosted on Acast. See acast.com/privacy for more information.

NYU Law professor and frequent MSNBC analyst Melissa Murray brings her genius perspective to the podcast this week, and explains the whys and wherefores of this intense Supreme Court term that has just come to a close. Plus, she has positive suggestions for what We, the People can do to keep our own checks and balances on the Court and lawmaking in general. There is some hope, and Professor Murray is here with it. That's not to say the M&M cookies Marissa bakes during the podcast don't help ease some of the ire of the Court's recent decision. Plus, Melissa recounts the inspiring reason she became a lawyer. Learn more about your ad choices. Visit megaphone.fm/adchoices

In the coming weeks, the Supreme Court of the United States will hand down decisions that could have major implications for LGBTQIA+ rights, racial justice, tribal sovereignty, and beyond. Melissa Murray and Jonathan discuss what's on the docket, why the Supreme Court seems more powerful (and conservative) than ever, and how we can get through this hot mess SCOTUS summer. Melissa Murray is a Professor of Law at NYU School of Law, where she teaches constitutional law, family law, criminal law, and reproductive rights and justice and writes about the legal regulation of intimate life. Melissa clerked for Judge Stefan Underhill on the District of Connecticut and for Justice Sotomayor when she served on the Second Circuit. When she's not reading the SCOTUS tea leaves, she's practicing the violin, reading People magazine, and keeping up with Meghan Markle, the Duchess of Sussex. You can follow Professor Murray on Twitter and Instagram @ProfMMurray. You can keep up with Strict Scrutiny on Twitter @StrictScrutiny_ and Instagram @strictscrutinypodcast. Crooked Media is on Twitter and Instagram @crookedmedia. Curious for more? Check out these episodes from the Getting Curious archive: Can State Legislatures Save Us? Whose Land Is This Land? What Happened To Separation Of Church And State? Follow us on Instagram @CuriousWithJVN to join the conversation. Jonathan is on Instagram @JVN. Transcripts for each episode are available at JonathanVanNess.com. Find books from past Getting Curious guests at bookshop.org/shop/curiouswithjvn. Our executive producer is Erica Getto. Our producer is Chris McClure. Our editor is Andrew Carson. Production support from Julie Carrillo and Emily Bossak. Our theme music is “Freak” by QUIÑ; for more, head to TheQuinCat.com. Learn more about your ad choices. Visit podcastchoices.com/adchoices

On today's show Professor Murray Sabrin discusses his American success story as well as thoughts on the Great Reset. GUEST OVERVIEW: Murray Sabrin, Ph.D. is emeritus professor of finance, Ramapo College of New Jersey. He is considered a “public intellectual” for writing essays about the economy in scholarly and popular publications in addition to his numerous appearances during the past three decades as a talk media guest commenting on political and social issues. He is the author of Tax Free 2000, Why the Federal Reserve Sucks; Universal Medical Care: From Conception to End-of-Life; Navigating the Boom/Bust Cycle; and most recently, The Finance of Health Care: Wellness and Innovative Approaches to Employee Medical Insurance. His commentaries can be followed at murraysabrin.substack.com. His latest book, an autobiography, From Immigrant to Public Intellectual: An American Story, was published November 2022. His Twitter is @msabrin and Facebook https://www.facebook.com/murray.sabrin. 

jQuery(document).ready(function(){ cab.clickify(); }); Original Podcast with clickable words https://tinyurl.com/2za269j6 Contact: irishlingos@gmail.com "More people are surviving invasive cancer now than ever". "Níos mó daoine ag teacht slán ó ailse ionrach anois ná riamh". The Director of the National Cancer Registry said that more people are surviving invasive cancer now than ever before due to the improvement in medical treatment and also because the disease is detected earlier. Dúirt Stiúrthóir na Clárlainne Náisiúnta Ailse go bhfuil níos mó daoine ag teacht slán ó ailse ionrach anois ná riamh de bharr an fheabhais atá tagtha ar chúrsaí cóireála leighis agus mar gheall, freisin, go n-aimsítear an galar níos luaithe. Professor Deirdre Murray pointed out that the medical treatment that is now available has greatly increased the longevity of the human wizard. Thug an tOllamh Deirdre Murray le fios go bhfuil an chóir leighis atá ar fáil anois tar éis cur go mór le fad saoil an draoi daoine. On the contrary, however, poor people are always left behind, says Professor Murray. Os a choinne sin, áfach, tá daoine bochta siar chun deiridh i gcónaí, arsa an tOllamh Murray. According to the latest figures from the National Cancer Registry, the number of people who have survived cancer has risen by 50% in ten years. De réir na bhfigiúirí is deireanaí ón gClárlann Náisiúnta Ailse, tá an líon daoine a tháinig slán ó ailse ardaithe 50 faoin gcéad le deich mbliana. For the first time ever, according to the statistics, there are over 200,000 people who have or have had cancer in their lives, that's one in every 24 of the entire population of the State. Den chéad uair riamh, de réir an staidrimh, tá os cionn 200,000 duine a bhfuil nó a raibh ailse orthu fós ina mbeatha, sin duine as gach 24 de dhaonra iomlán an Stáit. Speaking on RTÉ, Professor Murray said that invasive cancer is the type of cancer that can spread from where it was first found to other parts of the body. Ag labhairt di ar RTÉ, dúirt an tOllamh Murray gurb é is ailse ionrach ann an cineál ailse a d'fhéadfadh leathadh ón áit ar aimsíodh é i dtosach go dtí codanna eile den chorp. She also confirmed that lung cancer is more than any other type of cancer and is the leading cause of death for patients. Dhearbhaigh sí freisin gurb é an ailse scamhóg thar aon chineál ailse eile is mó is cionsiocair le hothair ag fáil bháis. It is still not entirely clear, said Professor Murray, how the Covid-19 pandemic has affected cancer. Níl sé iomlán soiléir fós, a dúirt an tOllamh Murray, cé mar a chuaigh an phaindéim covid 19 i gcion ar chúrsaí ailse. Currently, she said, it appears that during the pandemic, not as many types of cancer were being diagnosed as before. Faoi láthair, ar sí, dealraíonn sé nach raibh an oiread cineálacha ailse á ndiagnóisiú i gcaitheamh na paindéime agus a bhí roimhe. It remains to be confirmed, however, whether there are more people in the final stages of the disease than before the pandemic. Tá sé fós le deimhniú, áfach, an bhfuil níos mó daoine i gcéimeanna deiridh an ghalair ná a bhí roimh an bpaindéim. The appropriate figures are still being investigated but it shows the importance of early screening. Tá na figiúirí cuí fós á n- iniúchadh ach léiríonn sé, ar sí, an tábhacht a bhaineann le scagthástáil luath.

This week, please join author Guest Host Mercedes Carnethon, Author Brian Bergmark, and Associate Editor Parag Joshi as they discuss the article “Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.” Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your co-host. I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center in Duke National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley, Associate Editor, Director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Well Carolyn, this week's feature, non-high density lipoprotein cholesterol levels in statin treated patients with elevated cholesterol. We're going to hear from the TRANSLATE-TIMI 70 study. But before we get to that, how about we grab a cup of coffee and discuss some of the other articles in the issue? Would you like to go first? Dr. Carolyn Lam: I would. And by the way, that feature is going to be all exciting. It was discussed at the American College of Cardiology. But okay, how about from cholesterol to vitamins? Let's start with the Greg quiz. Greg, which vitamins have been associated with arterial calcification? Is it A, B, C, D, E? Dr. Greg Hundley: I'm going to pick E and K. Dr. Carolyn Lam: You're smart. Indeed. Vitamin K2, also known as menaquinone-7 is the most effective co-factor for the carboxylation of proteins involved in the inhibition of arterial calcification. Furthermore, combined low vitamin K and low vitamin D have been associated with increased all-cause mortality risk. And so, today's paper is from Dr. Diederichsen from Odense University Hospital in Denmark and colleagues really present the first double-blind, randomized controlled trial to test whether vitamin K2, a drug-targeting processes of calcification in addition to vitamin D, could slow the progression of aortic valve calcification and stenosis. So, in a randomized double-blind multicenter trial, men from the community with an aortic valve calcium score above 300 arbitrary units on cardiac non-contrast CT were randomized to daily treatment with 720 micrograms of vitamin K2 plus 25 micrograms of vitamin D or matching placebo for 24 months. And the primary outcome was the change in aortic valve calcium score. Dr. Greg Hundley: Carolyn, so menaquinone-7 and aortic valve score. So, what were the results? Dr. Carolyn Lam: Menaquinone-7 had no major effect on the progression of aortic valve calcification as assessed by CT or echo. High-dose menaquinone-7 was, however, safe and well tolerated. Now, some limitations is that this external validity is limited to men aged 65 to 74 with aortic valve calcification scores of greater or equals to 300 arbitrary units. Thus, caution is needed if we extrapolate these findings and other pathways need to be explored in order to identify an effective therapy for this unmet clinical need. Dr. Greg Hundley: Wow, very nice Carolyn. Well, my first article comes to us from Dr. Michael Laflamme from the University Health Network. And Carolyn, human pluripotent stem cell-derived cardiomyocytes or hPSC-CMs exhibit promise for application in cardiac regeneration, but their translational potential is limited by an immature phenotype. So Carolyn, this research team hypothesized that large scale manufacturing of mature hPSC-CMs could be achieved via culture on polydimethylsiloxane, and we're going to call that PDMS, lined roller bottles and that the transplantation of these cells would mediate better structural and functional outcomes then with conventional immature hPSC-CMs populations. Dr. Carolyn Lam: Oh, that's neat, Greg. So, what did they find? Dr. Greg Hundley: Right, Carolyn. So, these authors demonstrated the economic generation of greater than one times 10 to the eighth mature hPSC-CMs per PDMS line roller bottle. And compared to their counterparts, PDMS matured hPSC-CMs exhibited increased cardiac gene expression and more mature structural and functional properties in vitro. More importantly, intracardiac graphs formed with PDMS matured myocytes showed greatly enhanced structured alignment, better host graft electromechanical integration, less pro arrhythmic behavior, and greater beneficial effects on contractile function. So in summary, Carolyn, this team describes practical methods for the scale generation of mature human pluripotent stem cell-derived cardiomyocytes and provide the first evidence that the transplantation of more mature cardiomyocytes yields better outcomes in vivo. And there's a wonderful editorial by Professor Murray entitled Flexing Their Muscles: Maturation of Stems Cell-Derived Cardiomyocytes on Elastomeric Substrates to Enhance Cardiac Repair. Dr. Carolyn Lam: Wow! That's really significant. Thank you, Greg. Well, the next paper is the largest genome-wide association meta-analysis of plasma ACE2 levels in over 28,000 individuals. And this is from Dr. Xia Chen from Fudan University and Dr. James Wilson from University of Edinburgh in UK, and their colleagues. And guess what, it focuses on severe acute respiratory syndrome coronavirus 2, the etiologic agent of COVID 19. And we know that that enters human cells using the ACE2 protein as a receptor. ACE2 is thus key to the infection and treatment of the coronavirus. ACE2 is highly expressed in the heart, respiratory and gastrointestinal tracts, playing important regulatory roles in the cardiovascular and other biologic systems. Dr. Greg Hundley: Wow, Carolyn. ACE2, and also a very important topic here with SARS-COVID-2. So, what did they find? Dr. Carolyn Lam: First, the overall heritability of ACE2 level is 16% of which 30% can be explained by 10 protein quantitative trait loci identified in this study. ACE2 level is genetically correlated with both COVID-19 and cardiovascular. Elevated ACE2 levels show a causal relationship with COVID-19 severity, hospitalization and infection as shown by Mendelian randomization analyses. ACE2 regulatory variants are enriched on DNA methylation sites in immune cells. Dr. Greg Hundley: Wow, Carolyn. So, elevated ACE2 and a causal relationship with COVID-19 severity. So tell us, what are the clinical applications of this really nice study? Dr. Carolyn Lam: The causal evidence of ACE2 suggests that pharmacological inhibition of circulating ACE2 may be a promising approach for treating COVID-19 or its comorbidities. Transcription factors that play essential roles in ACE2 generation could provide alternative paths to pharmacological modulation of ACE2 plasma levels. The genetic correlations between ACE2 and both COVID-19 and cardiovascular disease imply that the cardiovascular complications seen in COVID-19 patients may be intrinsic to the disease and mechanically or/and mechanistically-driven by ACE2. Isn't that neat? Dr. Greg Hundley: You bet, Carolyn. Boy, what an exciting issue. And we've got other articles in this issue. Dr. Carolyn Lam: Yeah. Now, let me start this time. There's an exchange of letters between Drs. Duan and Chang regarding the article “Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo.” There's a Perspective piece by Dr. Morris, “The Updated Heart Failure Guidelines: Time for a Refresh.” Love that piece! There's an AHA Update piece (AHA President's Page) by Dr. Elkin on The Road to Equity in Brain Health, and ECG challenge by Dr. Kolominsky, Electrical Extremists in a Critically ill Patient, and an On My Mind Paper by Dr. Paulus entitled “Border Disputes Between Heart Failure Phenotypes.” Dr. Greg Hundley: Wow, Carolyn. And I've got two Research Letters. The first from Professor Groeneveld entitled “Prevalence of Short-Coupled Ventricular Fibrillation in a Large Cohort of Dutch Idiopathic Ventricular Fibrillation Patients.” And then a second Research Letter from Professor Yamashita entitled “Single Cell RNA Sequence Reveals a Distinct Immune Landscape of Myeloid Cells in Coronary Culprit Plaques Causing Acute Coronary Syndrome.” Well Carolyn, now, we get to go onto our feature, vupanorsen on non-high-density lipoprotein cholesterol levels and catching up with TIMI 70. Dr. Carolyn Lam: Let's go. Dr. Mercedes Carnethon: So, good morning listeners. I'm really pleased to invite you to this episode of our Circulation on the Run podcast. For those of you who don't hear me often, I'm stepping in as a guest host today. My name is Mercedes Carnahan from the Northwestern University Feinberg School of Medicine. And I'm really excited to be joined today by Dr. Brian Bergmark, and associate editor, Dr. Parag Joshi. And we will have today Dr. Bergmark discussing his new article published with us on the effects of vupanorsen on non-HDL cholesterol levels in the TRANSLATE-TIMI 70 trial. We're really thrilled to have you with us here today, Brian, to talk about the really important findings coming from this trial. So to start us off, just tell us, what did you find? Dr. Brian Bergmark: Great. Thank you so much. It's really a pleasure to be here and I'm grateful for the opportunity. So, in the big picture, despite numerous agents to reduce lipid-mediated cardiovascular risk, obviously, residual risk remains and there are novel targets to address that risk. One of them is angiopoietin-like 3, which is a protein made in the liver. Angiopoietin-like 3 or ANGPTL3 inhibits lipoprotein lipases among other lipases, and thereby interferes with metabolism of triglyceride-rich lipoproteins. And so, the idea here was that if ANGPTL3 could be inhibited that LPL or lipoprotein lipase function could be augmented and metabolism of these lipoproteins could be augmented. And so, what we did is we took patients with an elevated non-HDL cholesterol, at least 100 milligrams per deciliter, and elevated triglycerides, 150 to 500 milligrams per deciliter, and randomized them to placebo or one of seven doses of vupanorsen, which is an antisense oligonucleotide, which inhibits the synthesis of ANGPTL3 in the liver. We then follow them to see what the impact was on their non-HDL cholesterol, as well as other lipid parameters through 24 weeks. Dr. Mercedes Carnethon: Thank you so much. It's a wonderful design, and I'm really excited to hear a little bit more about what you found. Dr. Brian Bergmark: Great. So, the primary endpoint was the change in non-HDL cholesterol from baseline to 24 weeks. And we did find that all vupanorsen regimens reduced non-HDL cholesterol in a statistically significant manner. The magnitude of that effect was up to 27.7% in one of the dose arms or about 28%. We also saw a statistically significant reductions in the target ANGPTL3 up to about a 95% reduction in the highest dose arm, as well as statistically significant reductions in triglycerides at all of the dose regimens. The effect on LDL cholesterol and on apolipoprotein B or apo B was variable across regimens and only statistically significant in a few of the dose arms. We also found several safety signals. One, there appeared to be higher rates of injection site reactions in the skin at higher total monthly doses. We also found higher rates of elevation in liver enzymes, AST and ALT at higher total monthly doses. And we also found significant increases in hepatic fat fraction or the fat content of the liver at higher total monthly doses. Dr. Brian Bergmark: In the end, we found that while statistically significant, the magnitude of the reduction in non-HDL cholesterol was modest as was the reduction in apo B. And so, the goal here was to find a dose that might have a reduction of a magnitude that would be clinically meaningful for cardiovascular risk reduction. We were underwhelmed by the magnitude of that reduction, and then it was paired with these safety signals, which if there's interest, we could get into more detail in our thinking about why those occurred, what the implications are, but suffice it to say that there were medically meaningful safety concerns paired with a modest reduction in non-HDL cholesterol. Dr. Mercedes Carnethon: Thank you for that excellent summary. Before I turn it over to the associate editor, I read this with great interest, and in particular, looking at one of the first figures in the paper, which is demonstrating the adjusted change at 24 weeks across different doses and based on how frequently the doses were given the four week as compared with the two week. And one thing that really stood out to me was the clear dose response with the four week regimens with the higher doses appearing to demonstrate the greatest reductions but a less clear signal with the two week regimens. Do you have any hypotheses about why these patterns appeared so different? Dr. Brian Bergmark: Yeah. It's a great question. So, the responsiveness of this is something of interest here I think. So, if you look at the effect of the drug on its target, ANGPTL3, there is a very clear dose response, so there's no doubt that higher doses were impacting the target ANGPTL3 to a greater extent. So, one of the most direct effects would be on triglycerides, one of the most direct lipid effects, and that appears pretty close to a dose response relationship within each of these frequencies of administration. But once you start getting to non-HDL cholesterol, it starts to break down a bit. And is it simply because of random chance or is there actually something distinct going on with how the lipids are being metabolized? Dr. Brian Bergmark: That is something we are diving into. So, the hope would be that we actually reduce apo B, the number of these actually circulating lipoproteins as has been demonstrated with the monoclonal antibody. It's possible that with this other different mechanism in the antibody, this antisense oligonucleotide, perhaps, we're simply shifting the content of these lipoprotein molecules and decreasing the triglyceride content but not actually meaningfully modifying the amount of apo B, LDL cholesterol. And that might be part of what we're seeing with the more muted relationship between dose and the effect on non-HDL cholesterol. I don't know for certain we are diving into this a bit more with other lipid fractions, et cetera. Dr. Mercedes Carnethon: Oh, well, thank you so much for that explanation. I know that a number of people, this was extremely well received when shared at the recent American College of Cardiology meetings, and so I was really thrilled to find that this was appearing in the journal circulation. So Parag, I'm really interested in hearing your perspectives on why we knew that this was certainly a priority paper for us. Dr. Parag Joshi: Yeah. Let me first start, Brian, congratulations. Fantastic work. And we were excited to receive the paper. I think really hard to pull off trials right now or in the last couple years, so kudos to you. And I echo the sentiments from Mercedes. This is great work. Really important space, the residual risk space I think is very important of course and is critical to moving forward with improving cardiovascular health. So, one of the big picture questions and as we get to this triglyceride-rich lipoprotein lowering space, certainly, there's strong associations with residual risk, but can we impact that risk? And here, we're starting to explore that. And I think when you think of the lipoprotein space, many of us are interested in what is the effect on these lipoproteins as opposed to the cholesterol content or the triglyceride content. And non-HDL cholesterol or apo B, clearly, the better, stronger markers for that risk, so we were really excited to see this paper.   Dr. Parag Joshi: And as Brian mentioned, unfortunately, not the strongest impact here on those measures. And I want to dive into that a little more because I think that carries significant implications for the space, and I'd love to hear your thoughts on that. But overall, really fantastic work. I think my first question really is around the apo B aspect of this and the less than anticipated lowering of those levels. You hinted at this in terms of, is this shuffling cholesterol and triglycerides across particles, or do you think this could be the mechanism by which this happens through ANGPTL3? You do inhibit the levels quite a bit. Did we just miss that... Is this not the right target? What do you think? Dr. Brian Bergmark: Yeah, it's a great question. I do think the target itself holds great promise. Obviously, a monoclonal antibody against this same target results in major reductions in apo B, LDL cholesterol, and the latter through a mechanism that is not really known but is not dependent on the LDL receptor, and therefore has real clinical utility that's approved for people with familial homozygous hypercholesterolemia. Beyond that, of course, in genetic studies, there's a clear association with loss of function in the ANGPTL3 gene and lower levels of all of these lipids, lower rates of coronary artery disease, et cetera. Dr. Brian Bergmark: So, I think it's not that this pathway is not promising and actually already being taken advantage of, I think it's that this particular agent acting through this mechanism was not able to achieve a necessary efficacy with reasonable safety. Some genetic data suggests that there is not actually a dose response between a reduction or loss of function in ANGPTL3 and reduction in apo B or lower levels of apo B and non-HDL cholesterol, but it really requires your complete elimination of ANGPTL3 function, which is probably, likely achieved with the monoclonal antibody. And so, even though we had quite large reductions with the antisense oligonucleotide, perhaps, we just didn't cross that threshold that's needed to modify the lipid panel in the way that would've been clinically meaningful. Dr. Parag Joshi: Yeah. I think that's fantastic as you allude to with evolocumab and the impact that has on apo B levels. I didn't think of it as a threshold effect, but that makes a lot of sense as maybe that just getting to that tipping point is where the issue is here. In terms of the liver signal, what were your thoughts on that? And is that something that we should expect to see in ASOs or do you think it's specific to this compound? Dr. Brian Bergmark: Yeah, I don't know. That was unexpected. Right, there are two liver signals and it's unclear how related they are. One is the inflammation of the liver as indicated by the elevation in enzymes, and then the other is the fat accumulation. So with respect to the fact, if anything, genetic data suggests perhaps loss of function in ANGPTL3 might result in lower rates of hepatic steatosis. In animal models, the antisense oligonucleotide reduces liver fat, and so there's, there was promise going into this that this could actually be beneficial for non-alcoholic fatty liver disease. And additionally, there's not data to suggest that the monoclonal antibody increases liver fat. So, there's not a lot to support this as being an on-target effect that by inhibiting ANGPTL3, by that pathway, the liver fat was increased. So, I think a reasonable person might wonder whether this was an off-target effect of the drug. Dr. Brian Bergmark: By what mechanism that occurred, I don't know, what the implications would be for other related agents, I don't know. And then similarly, the liver enzyme elevations, is that related to this? I'm not exactly sure, but also unexpected and I think off-target. But that sort of intrinsic to this mechanism of hepatic targeting, is this something we need to be worried about for other agents in this class or not? I don't know. Obviously, we can't answer that from this single study. We are going to dive into it a bit more to try to overlay patients with hepatic fat accumulation, liver enzymes, et cetera. Of course, both of those happen more at higher doses. How much we can really parse this? I'm not sure yet. Dr. Parag Joshi: Yeah. That's really fascinating. I think the appeal of this paper to the circulation audience is that you have a really exciting novel target and pathway to explore here but somewhat divergent results from what's existing in this space. And I think that raises a lot of questions, really interesting questions going forward for this space. For the ANGPTL3 pathway, what do you see there coming down the line or what are your thoughts on that going forward for this target and ways to approach risk related to it? Dr. Brian Bergmark: Yeah. Great. Thank you. Yeah. No, so I agree. I think moving into this other end of the spectrum of triglyceride-rich lipoproteins, et cetera, I think this is where we're headed and this is why we do the trial. We weren't expecting these things that's why you do this experiment, and this is what we found. So now, where do we go from here? So there are, of course, other ways beyond the monoclonal antibody of targeting ANGPTL3 specifically. There's siRNA, there is gene therapy being investigated. So, I think all of them hold an great promise. And of course, we will need to see as those therapies move along what the actual trials show. And then there are, of course, other pathways that are of interest, APOC3, for instance. So, I think there's a lot more in this space that's coming down the line. Dr. Parag Joshi: Yeah, absolutely. I think it's a really exciting space, and we're really happy to get this paper as one piece of that whole puzzle. So, thank you. Dr. Mercedes Carnethon: Yes. And I echo that as well. And as a methodologist myself, I'm always really pleased to see such well-designed studies. I think this was sophisticated in many aspects in testing different dosing and different timing of the dosing. And also, I'm really impressed by your inclusion criteria, particularly when I noted that 44% of the participants were female, and that you reported those stratum-specific effects. I just had a final question as we wrap up. You acknowledge a nominally significant interaction by sex and I see, for example, that it appears that the magnitude is larger possibly in the relatively smaller subset of females as compared with males. Is this something to pay attention to or do you think this is just some type of an artifact related to greater variability because the group is smaller? Dr. Brian Bergmark: Yeah, it's a good question. So, this is the burning question. We had no a priority reason to suspect that biologically and we are not adjusting for multiple testing in the key value of 0.04. So just to put my money down, I would say, I would guess it's random chance. We found it. It's worthy of looking into a bit more. There were, of course, the important implications for other drugs, et cetera. So, I think it's worth diving into as we will, but are we likely to uncover some biological difference? I doubt it. I wouldn't guess. There are other subgroups where I think at least upfront, you might expect there could be a difference. So, there are thoughts about insulin's effect on LPL. Could diabetes status have an interaction with the drug? I think though not statistically significant, it's also something worth looking into that group and the subfractions of the lipid panel and all of that stuff. So, I think it's all worth looking into but cautiously with the constraints. Dr. Mercedes Carnethon: Well, thank you so much for that explanation. And I've really enjoyed this discussion with you today, Brian, and you, Parag. I've certainly learned a lot and I'm really excited to see this excellent work coming out in the journal circulation. So, thank you very much for your time this morning and thank you to our listeners. Wrapping up this episode of Circulation on the Run. Dr. Greg Hundley: This program is copyright of the American Heart Association 2022. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ahajournals.org.

Co-Dean Kimberly Mutcherson is joined by Melissa Murray, Frederick I. & Grace Stokes Professor of Law at NYU and Faculty Director at the Birnbaum Women's Leadership Network. Professor Murray discusses the reproductive justice movement, its relationship to reproductive rights, and the makeup of the U.S. Supreme Court. She also shares some thoughts on SB 8, the controversial anti-abortion law in Texas. Professor Murray is one of the hosts of the Strict Scrutiny Podcast, a podcast by three women about the Supreme Court and the legal culture that surrounds it. The Power of Attorney is produced by Rutgers Law School. With two locations minutes from Philadelphia and New York City, Rutgers Law offers the prestige and reputation of a large, nationally-known university combined with a personal, small campus experience. Learn more by visiting law.rutgers.edu. Production Manager: Margaret McCarthy Series Producer: Nate Nakao Editor: Nate Nakao --- Send in a voice message: https://anchor.fm/rutgerslaw/message

In this episode Dr. Marta Di Forti and Professor Sir Robin Murray discuss the link between cannabis use and psychotic illness in depth, including: - How cannabis has changed over recent decades- The effect of cannabis on the incidence of psychosis- How cannabis can produce psychotic symptoms in a laboratory setting- The potential role of the endocannabinoid system in humans- The cannabis clinic run by Dr. Di Forti in the South London and Maudsley NHS trustDr. Di Forti is a psychiatrist and senior clinical fellow and senior lecturer at the Institute of Psychiatry, Psychology and Neuroscience at King's College London and is now regarded as one of the leading researchers in the world in the field of cannabis and psychosis.Professor Murray is a psychiatrist and Professor of Psychiatric Research at the Institute of Psychiatry, Psychology and Neuroscience at King's College London, and considered a world expert in psychotic conditions such as schizophrenia. Interviewed by Dr. Anya Borissova.  Do you have questions comments for feedback? Email us here-  podcast@maudsleylearning.com -  Follow us here: Twitter @maudsleypodcast Instagram @maudsleylearningpodcast

Welcome to episode 27.  Are you searching for purpose-driven work?  Does your inner voice tell you to start a passion project or build your own company? The Kourting Happiness Meaningful Work Fuels Me series is here to help.  We kick it off with Professor Tira Murray.  She is the founder of the Female Academic, a platform that serves women of color in higher education.  Our host, Dr. Kortni Alston, talks with Professor Murray about her community and how she created it while working full-time at a university.  Join the Kourting Happiness Podcast Community on Facebook: https://www.facebook.com/groups/683431425607990   

In this episode, I speak with Professor Murray Drummond of Flinders University, South Australia.His research extends into the social constructs of masculinity in sport, mental health in young sportspeople in sport as well as body image and how it plays a role in the development in mental health in men.This conversation is a fascinating topic, in how men perceive themselves in society and how the pathway into sport plays a vial role in building not only good athletes but good men in our societies.This episode is sponsored by Sport YogiFor Athletes that want to Breathe, Think and Move Better...The Sport Yogi app is now available.Download atiOSAndroidVisit sportyogi.com for moreConnect with Lewis at:Instagram: @lewishatchettFor more on the podcast visit www.lewishatchett.com/podcast

Words cannot describe how honoured and thrilled we are to share this incredibly special episode featuring Professor Emeritus Stephen Murray. Professor Murray is an evocative storyteller overflowing with fascinating historical tidbits about Gothic architecture, medieval clergy, the influence of electronic media and technology in architectural history research, and SO much more! We hope you enjoy! . . . Professor Emeritus Stephen Murray recently published a beautiful monograph on Amiens Cathedral titled, 'Notre-Dame of Amiens: Life of a Gothic Cathedral' available to purchase on the Columbia University Press website, Amazon, and anywhere else you buy books. As an advocate for accessible knowledge through electronic media, Professor Murray created a companion website to his monograph available here: http://projects.mcah.columbia.edu/amiens-arthum/  . Further, Professor Murray is a member of the 'Friends of Notre-Dame de Paris' the official 501(c)(3) charity leading the international fundraising efforts to rebuild and restore Notre-Dame Cathedral. . Modern Medieval jingle created by Trothgard: https://trothgardmusic.bandcamp.com/album/legends-of-alderley 

Chris Diamond in conversation with Professor Murray Pittock of the University of Glasgow on the 300th anniversary of the birth of Charles Edward Stuart.

In Art Is Everything (TriQuarterly Books, 2021), L.A. native Amanda Ruiz is a successful Chicana performance artist who is madly in love with her girlfriend, Xochitl. Amanda is about to enjoy a residency at the Guggenheim Museum in New York and plans to film a groundbreaking documentary in Mexico. Then Xochitl’s biological clock begins beeping, Amanda’s father dies, and Amanda is assaulted during an Uber ride. Her life and art are upended and she’s not sure how to get back on track. Written as a series of web posts, Instagram essays, Snapchat posts, rejected Yelp reviews, Facebook screeds, and streams-of-consciousness that merge volcanic confession with eagle-eyed art criticism, Art Is Everything is about a woman who has to grapple with being derailed. After earning her J.D. at Stanford Law School, Yxta Maya Murray clerked for two judges and then joined the Loyola Law School faculty in 1995. Recipient of an Art Writer’s Grant from the Andy Warhol Foundation, she published a one-act play about the Christine Blasey Ford hearings, titled Advice and Consent (LARB Books 2019) and was named a finalist for the National Magazine Awards in Fiction. Her scholarly work focuses on Community Constitutionalism, Criminal Law, Property Law, Gender Justice, and Law and Literature. Professor Murray has published in a number of law journals, where her most recent work concerns FEMA’s failures in Puerto Rico. As a novelist and art critic, she has published six books and won a 1999 Whiting Writer’s Award. Her seventh novel, Art Is Everything, is being published by TriQuarterly Books. When she is not teaching, reading, or writing, Murray enjoys running, photography, painting, and eating. I interview authors of beautifully written literary fiction and mysteries, and try to focus on independently published novels, especially by women and others whose voices deserve more attention. If your upcoming or recently published novel might be a candidate for a podcast, please contact me via my website, gpgottlieb.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

In Art Is Everything (TriQuarterly Books, 2021), L.A. native Amanda Ruiz is a successful Chicana performance artist who is madly in love with her girlfriend, Xochitl. Amanda is about to enjoy a residency at the Guggenheim Museum in New York and plans to film a groundbreaking documentary in Mexico. Then Xochitl’s biological clock begins beeping, Amanda’s father dies, and Amanda is assaulted during an Uber ride. Her life and art are upended and she’s not sure how to get back on track. Written as a series of web posts, Instagram essays, Snapchat posts, rejected Yelp reviews, Facebook screeds, and streams-of-consciousness that merge volcanic confession with eagle-eyed art criticism, Art Is Everything is about a woman who has to grapple with being derailed. After earning her J.D. at Stanford Law School, Yxta Maya Murray clerked for two judges and then joined the Loyola Law School faculty in 1995. Recipient of an Art Writer’s Grant from the Andy Warhol Foundation, she published a one-act play about the Christine Blasey Ford hearings, titled Advice and Consent (LARB Books 2019) and was named a finalist for the National Magazine Awards in Fiction. Her scholarly work focuses on Community Constitutionalism, Criminal Law, Property Law, Gender Justice, and Law and Literature. Professor Murray has published in a number of law journals, where her most recent work concerns FEMA’s failures in Puerto Rico. As a novelist and art critic, she has published six books and won a 1999 Whiting Writer’s Award. Her seventh novel, Art Is Everything, is being published by TriQuarterly Books. When she is not teaching, reading, or writing, Murray enjoys running, photography, painting, and eating. I interview authors of beautifully written literary fiction and mysteries, and try to focus on independently published novels, especially by women and others whose voices deserve more attention. If your upcoming or recently published novel might be a candidate for a podcast, please contact me via my website, gpgottlieb.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

19 August 2020 marks the 275th anniversary of the Raising of the Jacobite Standard by Charles Edward Stuart at Glenfinnan. Professor Murray Pittock, Trustee and history advisor to the National Trust for Scotland, takes Jackie Bird through this hugely important moment in Scotland's history.

Join Laura Turner and her guest Professor Greg Murray - Director of Swinburne's Centre for Mental Health. For a PDF (including full links) of Professor Murray's Pandemic Hacks - please email a request to our show producer jane.nield@crocmedia.comProf Greg Murray's Pandemic HacksThe aim of this information is to briefly introduce psychological approaches to maintaining mental health and wellbeing during the pandemic, and to direct readers to good quality, free online resources in Australia.Maintain WellbeingRoutine and daily structure are critical to wellbeing. Like pets and small children, our bodies want to know what’s happening next, and that’s why daily routines (when we get up, eat lunch, go to bed, etc.) are so important for our physical and mental wellbeingTry to make key daily events (particularly the time you get up) roughly the same 7 days a week. To help with sleep and energy, make sure you get out into the sunlight every day, preferably while exercising (e.g., walking). Always have a ‘wind down’ time in the evening before bed. If we try to solve problems after sunset, we often end up catastrophising and worrying (see below).It’s easy to lose sight of pleasures (the dog?) and simple distractions (Netflix?) when we are busy adjusting to new challenges. Doing things we enjoy creates positive feedback loops because it proves to the brain that we are safe and well. Any behaviour that feels routine and familiar is likely to be comforting at this time.Remember, just because some pleasant activities are not available, doesn’t mean none are. And don’t forget one of the great ‘virtuous cycles’: Humans feel less stressed when they focus on the needs of others. Cultivating gratitude for what you do have, and empathy for the challenges of others can be like a breath of fresh air. People find if they keep to their own personal ‘values compass’, life continues to be meaningful and rich despite misfortune.Manage AnxietyAnxiety is a natural part of our response to threat and uncertainty. Here are some tried and true self-help tools for managing anxiety.The power of planning: Write a list of current concerns down on paper. Pick the most pressing one. List all solutions (including ridiculous ones), then pick one to work towards. Write down the steps (including resources) needed to achieve the solution. Take action, and give yourself feedback about the outcome. What did you learn about the problem, the solution, and yourself? Repeat as necessary. The power of perspective: How we experience a situation depends on the view we take of it. You’ve probably heard of catastrophising (‘what if...’questions), but also be alert to black and white thinking (things are either ‘normal’ or ‘a disaster’),and emotional reasoning (‘it feels this way, so it is this way’). Also watch out for worry,which has two parts:(i) ruminating about the worst possible outcome, and(ii) forgetting about the coping resources we would actually use if things didn’t turn out as we want. The Power of Being Present: Our stress response encourages to have an emotional focus on future threats (that’s what the fight/flight system is adapted to do). An important antidote to stress and worry is to use the senses and the breath to bring attention to the present moment, and away from the silly jabbering of our thoughts (what the Buddhists call ‘monkey mind’). Simple meditation and breathing exercises take some practice, but have helped millions of people across thousands of years get through challenging life events.Some Tips From PhilosophyPeople have been dealing with challenges and crises, both personal and public, throughout history. One personal benefit of this challenging time could be that you explore the great traditions of coping with challenges and leading a good life.Buddhism provides a roadmap for wellbeing, which many non-Buddhists have experienced through meditation and mindfulness practices.Buddhism is a process philosophy, emphasising impermanence and flow. Buddhism also emphasises the interconnectedness of living things: “It is because our own human existence is so dependent on the help of others that our need for love lies at the very foundation of our existence. Therefore we need a genuine sense of responsibility and a sincere concern for the welfare of others.” Dalai Llama. The Stoic philosophers are a great comfort when life is really challenging. The Stoics emphasise courage as a virtue, and encourage us to keep focus on what we can control in difficult times. “Some things are within our power, while others are not. Within our power are opinion, motivation, desire, aversion, and, in a word, whatever is of our own doing; not within our power are our body, our property, reputation, office, and, in a word, whatever is not of our own doing.” (Epictetus)“The storm does not interfere with the pilot’s work, but only with his success. ... It is indeed so far from hindering the pilot’s art that it even exhibits the art; for anyone, in the words of the proverb, is a pilot on a calm sea.” (Seneca)Keep An Eye Out For the Gold Nugget...After traumatic experiences, about half of people report post-traumatic growth. That is, many people find benefits in going through difficult, even overwhelming experiences. This pandemic will not be traumatic for everyone by any means. But being thrown out of our routines can help us learn new things about ourselves and how we cope with life. In 3 years’ time, looking back on 2020, what new habits, insights, behaviours will you identify as personal benefits of this event? What do you think we, as a society and a global community, might say was the gold nugget in the pandemic?Seek Help If NecessaryIf you find negative emotions or thoughts are interfering with your everyday life, it might be time to seek help. Your GP is a good starting point, and you can also make contact with professionals via the web (phone-based services for a range of audiences can be found here: www.beyondblue.org.au/get-support/national-help- lines-and-websites). Online psychological treatments can be accessed for free at www.mindspot.org.au and https://www.mentalhealthonline.org.au/ , and for low cost at www.thiswayup.org.au. You can find a good psychologist in your area by visiting www.psychology.org.au/Find-a-Psychologist .Suicide and crisis support: If you are in an emergency, or at immediate risk of harm to yourself or others, phone emergency services on 000.Great Australian Lives is proudly brought to you by Tobin Brothers Funerals - to see videos of our guests like their Facebook page HERE.This program is produced, engineered and edited by Jane Nield.

Hey everyone! We have Professor Melissa Murray here with us today!! Tina fangirl the whole time!! This episode was recorded on Monday before the lawsuits, so, unfortunately, I couldn’t ask her anything about the lawsuits. Prof is a graduate of the University of Virginia and Yale Law School. She also clerked for Sonia Sotomayor, then of the US Court of Appeals for the Second Circuit, Errrkkkkk life goals for Tina!) and Stefan Underhill of the US District Court for the District of Connecticut. She is a member of the New York bar. Murray teaches constitutional law, family law, criminal law, and reproductive rights and justice, among other courses and she is a regular contributor on MSNBC. You can reach Professor Murray here Her Twitter: https://twitter.com/profmmurray And on the podcast she co-hosts StrictScrutiny https://twitter.com/StrictScrutiny_ http://strictscrutinypodcast.com/ Subscribe here: https://apple.co/30Qxwwa Topics we covered 1. If Meghan was one of your girlfriends, what would you tell her she’s doing right and what, if anything, would you advise her differently? 2. What piqued your interest in the duchess and when?  3. Duchess’s situation is the epitome of a situation where you’re butting up against people with unearned privilege who you outperform regularly. What lessons do you take from how she is handling her situation? And how can we apply those lessons in our daily lives  4. What do you think about the royal family’s seeming complicity or laissez-faire attitude about the press abuse? 5. More girlfriend questions, how would you advise her to protect her sanity in the face of the madness?  6. What has Meghan done that you are most proud of or can most relate to? Something where you said to yourself, “Now if I was in her position, that’s exactly what I would’ve done?” 7. What do you think is the difference between a political and humanitarian issue? How would you define each? Given whenever Meghan does something the U.K. press always tries to bin under political.    #istandwiththesussexes Mr. Gilbert's latest articles: http://bit.ly/30Q3dFQ and http://bit.ly/2oUnSvf   Charities we are supporting: http://bit.ly/2YuYhc9   If you click and purchase from the links below you will be supporting our platform For those looking for all of the smart set stuff in one place here you go! Tote http://bit.ly/2kyeL1z  Misha Shirt http://bit.ly/2mafeHn  V neck dress http://bit.ly/2m6RMuD Blazer http://bit.ly/2kPWI70 Slim fit tapered pants http://bit.ly/2klExWr Please don’t forget to send letters to Harry, Meghan, and Archie using this address!   The Duke & Duchess of Sussex Clarence House London SW1A 1BA England United Kingdom   Please subscribe YouTube https://www.youtube.com/channel/UCjMD_ukTo0t6ZfvOXP_y0xQ and hit the notification button!

Professor Murray Rae (on 'Beyond Conflict: Evolution, Science and God') Interview by Jamie Green on Radio One 91fm Dunedin

Professor Murray Rae (on 'Beyond Conflict: Evolution, Science and God') Interview by Jamie Green on Radio One 91fm Dunedin

Intro: Chandra’s mom is doing better: Minutes 0 to 1:30 Chandra’s mom is doing better although she is still in the hospital. She’s been getting physical therapy for her injuries and is focused on recovering. The rise of fascism: Minutes 1:30 to 4:30 Boris Johnson, a terrible racist with a superficial resemblance to Trump, has been appointed Prime Minister of England after Teresa May stepped down following the Brexit debacle. We talk about that and our disappointment with Robert Mueller’s testimony. The Affleck brothers and Matt Damon have films with questionable plots: Minutes 4:30 to 11:45 Ben Affleck and Matt Damon are reuniting on screen and co-writing a screenplay based on a 14th century revenge story of two best friends. One of them goes to war, comes back and accuses the other of raping their wife. No one believes the wife’s claim she was raped so their sentence is to fight to the death. If the husband loses his wife gets burned at the stake. Given Ben’s history of sexual harassment, and Matt’s history of discounting women’s MeToo stories, the plot sounds problematic at best. Casey Affleck is making his big return following two sexual harassment lawsuits. He’s directing and starring in a post apocalyptic film in which all women have been wiped out by a disease. We find the whole premise weak. Scarlett Johansson’s ugly engagement ring: Minutes 11:45 to 15:45 Scarlett Johansson, who is 34 and has been married and divorce twice, is engaged for the third time to Colin Jost of Saturday Night Live. She wore her engagement ring to Comic-Con and it is different to say the least. It’s a brown 11 carat diamond and it’s like a warped oval or like round teardrop shape on a curved black band. We think her engagement ring is ugly and talk about our favorite rings.  One in four women under 25 have stopped shaving their armpits: Minutes 15:45 to 20 According to research by Mintel and reported by Vogue at least one in four women under age 25 has stopped shaving their armpits. We’ve seen this trend on the red carpet a bit lately, although I’m sure Julia Roberts thinks she invented it. We give TMI about our shaving preferences and habits. Puff Diddy is dating Steve Harvey’s 22 year-old daughter: Minutes 20 to 22 Diddy, 49, is dating 22 year-old Lori Harvey, who used to date his son! We know because they were papped out together. User Feedback: Minutes 22 to 24 Thank you to Kimberly, Paula, Professor Murray and Diane for your awesome feedback! You can contact us at 434-218-3219 and please tweet us if you’re on Twitter, particularly if you’d like us to talk about a certain story. Comments of the Week: Minutes 24 to 26 My comment of the week is from Crowhood on the post about Casey Affleck’s new movie. I have a bonus comment of the week from Mia4s on a Brad Pitt and Leonardo DiCaprio post. Chandra’s comment of the week is from LadyMTL on her post about Naomi Campbell grocery shopping. Thanks for listening bitches!

Pictured: Nan Winton Matthew Bannister on Murray Gell-Mann, the American physicist who won the Nobel Prize for his work on the theory of elementary particles. He coined the name "quarks" for the fundamental building blocks of matter. Nan Winton, the first woman to read the TV news on the BBC. She faced discrimination in the male-dominated BBC newsroom. James McCord, the CIA agent who was involved in the Bay of Pigs and the Watergate break in. Gregory Gray, the Irish singer who went from boy band to cult musician. Interviewed guest: Professor Geoffrey West Interviewed guest: Graham Farmelo Interviewed guest: Tina Ellen Lee Interviewed guest: Maggie Brown Interviewed guest: Michael Carlson Interviewed guest: Tom Robinson Interviewed guest: Noel McLaughlin Producer: Neil George Archive clips from: The Key To The Universe: The Search For The Laws Of Creation, BBC Two 27/01/1977; Horizon, BBC Two 25/07/1964; Panorama, BBC One 21/09/1959; Panorama, BBC One 09/03/1959; Arena, BBC Two 15/03/1997; U.S. Senate Select Committee On The Watergate Affair, BBC Sound Archive 18/05/1973; Watergate: Inside The Scandal That Took Down A Presidency, ABC News 17/06/2017.

This Valentine's Day, we're joined by Melissa Murray, NYU Law professor and expert on the legal regulation of sex and sexuality. Professor Murray and host Emerson Sykes discuss the legal institution of marriage as it has been used by and against marginalized people, and consider the victories and setbacks in the fight for marriage — and nonmarriage — equality.

In this Special Brexit edition of Policy Guns and Money, Dr Isaac Kfir, Director of the National Security Program at ASPI speaks with two special guests for an insight into Brexit - the process and status. Isaac speaks first with Professor Philomena Murray of the School of Social and Political Sciences at the University of Melbourne. Professor Murray is a former diplomat and an internationally recognised expert on the European Union. Next, Isaac spoke with Dr Margherita Matera ( also from the School of Social and Political Sciences) who provided fascinating insights into what Brexit might mean in the security and defence context. Professor Murray: https://findanexpert.unimelb.edu.au/display/person13932 Dr Matera: https://www.findanexpert.unimelb.edu.au/display/person6511 Dr Kfir: https://www.aspi.org.au/bio/isaac-kfir & https://twitter.com/isaac_kfir

Our guest on this episode of C-SPAN's The Weekly is New York University Law Professor Melissa Murray. She walks us through two primary cases on abortion, Roe v. Wade in 1973 and Planned Parenthood v. Casey. Professor Murray offers her insights into what could happen moving forward and how a new Supreme Court Justice could impact the original decision. Learn more about your ad choices. Visit megaphone.fm/adchoices

See omnystudio.com/listener for privacy information.

A few weeks ago, I received the good fortune of being invited to attend a class that was hosted by, the premiere training and education organization in the country, for preparing and training real estates agents, mortgage loan officers, attorneys, judges, financial planners. The founder of ; Prof. Kelly Murray, J.D. is a graduate of Stanford University and Harvard Law School. She's also a faculty law professor at Vanderbilt University. What you'll hear on this episode is three special guests: Wendy Waselle, also known as Aunt Wendy. She's the co-founder of . We have Loan Officer , who I've known for over ten years and REALTOR   with twenty-six years of experience. What you're gonna hear, is their story about why they decided to become Divorce Specialists. We'll talk about some of the road blocks how to approach attorneys and why it's important to get properly educated and trained. Like any other specialty, you need training to be a specialist. Lastly, we're teaming up with Professor Murray, J.D. and hosting a free, educational webinar on the new tax changes in alimony taxation, how the new Tax Cut and Jobs Act affects divorces and we'll answer your questions about becoming a Divorce Specialist. You can register for the webinar . Or At: Learn More:  

This week on MIA Radio, we interview Professor Sir Robin Murray. Professor Murray is an Honorary Consultant Psychiatrist in the Psychosis Service located at the Bethlem Royal Hospital in South London. He is also a Professor of Psychiatric Research at the Institute of Psychiatry. His research covers epidemiology, molecular genetics, neuropsychiatry, neuroimaging, neuropsychology and neuropharmacology.  Professor Murray’s main research interest is finding the causes of schizophrenia and bipolar disorder, as well as developing better treatments for these disorders.He is perhaps best known for helping to establish the neurodevelopmental hypothesis of schizophrenia, and for his work on the environmental risk factors relating to schizophrenia, such as obstetric events and cannabis use. In 2011, Professor Murray was awarded a knighthood for services to medicine and he is the second most widely cited psychiatrist in the world outside the USA. In this interview we discuss: •How Professor Murray came to psychiatry and what sparked his interest in research into psychosis. •Professor Murray’s work to counter the concept of schizophrenia as a debilitating brain disease and how we came to appreciate the many factors that may contribute to psychotic illness. •The importance of recognising the influence of social factors in the causes of psychotic illness. •The differences between the Diagnostic and Statistical Manual (DSM V) and the International Classification of Diseases (ICD 11). •How psychiatric diagnoses compare and contrast to diagnoses in other branches of medicine. •The question of whether schizophrenia is a real entity or purely an artificial construct. •How antipsychotic drugs exert their effects and the mechanisms by which they may lead, in some cases, to dopamine supersensitivity. •How we should be  cautious about the long-term prescribing of antipsychotic drugs. •The effect that limited healthcare resources have on psychiatric diagnoses and treatments. •What the future may hold for research into and treatment options for psychosis. Relevant links: Professor Sir Robin Murray The Psychosis Service at the Bethlem Royal Hospital 30 Years on: How the Neurodevelopmental Hypothesis of Schizophrenia Morphed into the Developmental Risk Factor Model of Psychosis  Webinar: Is Schizophrenia Dead Yet? Thou shall not criticise our drugs To get in touch with us email: podcasts@madinamerica.com © Mad in America 2017

Professor Andrew Murray is a Professor of Law at London School of Economics, with a particular interest in New Media and Technology Law. On 14 November 2017, Professor Murray gave a lecture at the Faculty as a guest of CULS and CLR. The event was kindly sponsored by Clifford Chance.

In a wide ranging interview Dario talks to prolific film scholar Murray Pomerance. The discussion touches on everything from Zabriskie Point to The Force Awakes, from The Clouds of Sils Maria to The Bourne Identity, from Marnie to The Dark Knight Professor Pomerance demonstrates an in-depth knowledge, engaging presence and fascinating insights on all things cinema. Murray Pomerance is Professor in the Department of Sociology at Ryerson University, Toronto. His publications include Moment of Action: Riddles of Cinematic Performance (forthcoming), Marnie (BFI, 2014), Alfred Hitchcock's America (Polity, 2013), The Horse Who Drank the Sky: Film Experience Beyond Narrative and Theory (Rutgers 2008), and An Eye for Hitchcock (Rutgers 2004), among others.He has edited or co-edited numerous volumes, including The Last Laugh: Strange Humors of Cinema (Wayne State, 2013), Hollywood's Chosen People: The Jewish Experience in American Cinema (Wayne State, 2012), Shining in Shadows: Movie Stars of the 2000s (Rutgers 2011), and Cinema and Modernity (Rutgers 2006), among others. In August 2009, he appeared on Broadway in conjunction with a performance of The 39 Steps and in August 2013 his visual essay (co-authored with R. Barton Palmer) appeared on the Criterion DVD of John Frankenheimer's Seconds. For further details and publications click here.

This week our special guest is Professor Murray Straus, a pioneering researcher on the subjects of sexual violence, intimate partner violence, and child abuse. Straus is possibly the most influential researcher on this issue in the academic world, with a career going back to the 1950s. He serves as Professor of Sociology and founder and Co-Director of the Family Research Laboratory at the University of New Hampshire, a position he has held since 1968. Call in with your questions or just listen to this amazing man's career and findings and the many, many studies he has been a part of crafting.

Professor Murray Rae of the Department of Theology and Religion presents his Inaugural Professorial Lecture on the topic of “Theology and the Pursuit of Truth”. 13 October 2011.

Professor Murray Rae of the Department of Theology and Religion presents his Inaugural Professorial Lecture on the topic of “Theology and the Pursuit of Truth”. 13 October 2011.

Professor Murray Rae of the Department of Theology and Religion presents his Inaugural Professorial Lecture on the topic of “Theology and the Pursuit of Truth”. 13 October 2011.

Professor Murray Rae of the Department of Theology and Religion presents his Inaugural Professorial Lecture on the topic of “Theology and the Pursuit of Truth”. 13 October 2011.

Professor Murray Rae of the Department of Theology and Religion presents his Inaugural Professorial Lecture on the topic of “Theology and the Pursuit of Truth”. 13 October 2011.

Professor Murray Rae of the Department of Theology and Religion presents his Inaugural Professorial Lecture on the topic of “Theology and the Pursuit of Truth”. 13 October 2011.